Want to see GRI full AI Analyst Report?
GRI Stock Chart & Stats
$1.45
-$0.05(-3.45%)
At close: 4:00 PM EDT
$1.45
-$0.05(-3.45%)
Day’s Range― - ―
52-Week Range$1.36 - $80.36
Previous CloseN/A
Volume6.87K
Average Volume (3M)82.65K
Market Cap
$3.61M
Enterprise Value-$7.71
Total Cash (Recent Filing)$10.95M
Total Debt (Recent Filing)$44.00K
Price to Earnings (P/E)―
Beta2.29
Next Earnings
May 20, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-80.38
Shares Outstanding2,186,115
10 Day Avg. Volume33,303
30 Day Avg. Volume82,652
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.11
Price to Sales (P/S)0.00
P/FCF Ratio-0.07
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$32.00Price Target Upside2106.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.77
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory DifferentiationOrphan Drug Designation can provide market exclusivity, tax credits, fee waivers and enhanced FDA engagement, improving GRI-0621's development economics and strengthening its position in rare fibrotic diseases.
Low Financial LeverageVery low debt reduces solvency pressure and interest obligations, while the rebuilt equity base provides greater balance-sheet stability as the company funds clinical development, although it does not remove future financing needs.
Clinical ValidationPositive Phase 2a results provide clinical support for GRI-0621 and may improve the probability of advancing the program, attracting partners or obtaining financing as the company develops therapies for progressive fibrotic disease.
Bears Say
Pre-revenue Business ModelGRI Bio has no commercial product revenue to offset research and development costs, leaving its financial performance dependent on clinical progress, external funding and potential future partnerships or approvals.
Persistent Operating LossesSizable and persistent losses indicate that current programs are consuming capital without generating operating returns. Continued development spending could keep profitability distant and increase dilution risk if financing is required.
Deepening Cash BurnIncreasing cash outflows directly constrain the time available to advance clinical programs without new capital. Because losses are largely cash-based, the company has limited accounting protection and remains reliant on financing.
GRI Bio News
GRI FAQ
What was Gri Bio, Inc.’s price range in the past 12 months?
Gri Bio, Inc. lowest stock price was $1.36 and its highest was $80.36 in the past 12 months.
What is Gri Bio, Inc.’s market cap?
Gri Bio, Inc.’s market cap is $3.61M.
When is Gri Bio, Inc.’s upcoming earnings report date?
Gri Bio, Inc.’s upcoming earnings report date is May 20, 2027 which is in 269 days.
How were Gri Bio, Inc.’s earnings last quarter?
Gri Bio, Inc. released its earnings results on Aug 19, 2026. The company reported -$0.91 earnings per share for the quarter, beating the consensus estimate of -$1.24 by $0.33.
Is Gri Bio, Inc. overvalued?
According to Wall Street analysts Gri Bio, Inc.’s price is currently Undervalued.
Does Gri Bio, Inc. pay dividends?
Gri Bio, Inc. does not currently pay dividends.
What is Gri Bio, Inc.’s EPS estimate?
Gri Bio, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gri Bio, Inc. have?
Gri Bio, Inc. has 2,186,115 shares outstanding.
What happened to Gri Bio, Inc.’s price movement after its last earnings report?
Gri Bio, Inc. reported an EPS of -$0.91 in its last earnings report, beating expectations of -$1.24. Following the earnings report the stock price went up 1.17%.
Which hedge fund is a major shareholder of Gri Bio, Inc.?
Currently, no hedge funds are holding shares in GRI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gri Bio, Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
GRI Stock 12 Month Forecast
Average Price Target
$32.00
▲(2106.90% Upside)
Technical Analysis
Ownership Overview
26.20%
Insiders
0.36% Mutual Funds
― Other Institutional Investors
72.46% Public Companies and
Individual Investors